Pharming Group N.V.

Board/Management Information • Mar 31, 2009

PHARMING PROPOSES NEW MEMBERS FOR SUPERVISORY BOARD

Leiden, The Netherlands, March 31 2009. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it will propose Messrs. J. Ernst and A. de Winter as new members for its Supervisory Board at the upcoming Annual General Meeting of Shareholders on April 15, 2009.

Mr. Ernst (69), German citizen, has extensive senior level experience in the field of pharmaceutical development and marketing. From 1969 until 1989 he held several positions at Kali-Chemie (subsidiary of Solvay SA), including Head of Pharmaceutical Marketing and Head of Pharmaceutical Division. In 1980, Mr Ernst continued his career at Solvay and held several positions until he retired in 2004. Amongst other, he was member of the Board of Pharmaceutical Division, CEO of Health Divisions, Member of the Executive Committee, General Manager Pharmaceutical Sector and Supervisory Director and member of the Executive Committee. Mr. Ernst holds an ISMP Degree from Harvard University and a MBA from the University of Cologne (Germany).

Mr. de Winter (56), Dutch citizen, has extensive financial experience. He started his career at AMRO Bank in 1980. In 1990, Mr. de Winter became senior Advisor Corporate and Institutional Finance at NIBC (formerly 'De Nationale Investerings bank'). From 1998 till last year, as Director of Listing & Client Services and Director, he was responsible for several listing and issuer relations activities, including execution and placement of capital market transactions and new listings on the Amsterdam Stock Exchange. Mr. de Winter is currently Associate Partner of First Dutch Capital. He holds a Law Degree from Erasmus University, the Netherlands, specializing in corporate law.

The Annual General Meeting of Shareholders will be held on April 15, 2009 at 15:00 hrs CET at the offices of the Company in Leiden. The agenda with explanatory notes thereto (including data concerning the proposed new members of the Supervisory Board), proxy form, the Annual Report 2008 and route description are available for Shareholders at the offices of the Company as of today. Copies of these documents can be obtained free of charge and will also be available at the Company's website (www.pharming.com) as of today.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400